{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:41:12Z","timestamp":1790008872774,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/tpj.2011.33","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T10:07:11Z","timestamp":1312884431000},"page":"476-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"P","family":"Biason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Hattinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Talamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Alberghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Scotlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Zanusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"BFtpj201133_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1517\/14728214.2010.505603","volume":"15","author":"CM Hattinger","year":"2010","unstructured":"Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M . Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010; 15: 615\u2013634.","journal-title":"Expert Opin Emerg Drugs"},{"key":"BFtpj201133_CR2","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1158\/1078-0432.CCR-05-0165","volume":"11","author":"OS Bruland","year":"2005","unstructured":"Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O . Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005; 11: 4666\u20134673.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"BFtpj201133_CR3","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3949\/ccjm.77.s1.05","volume":"77","author":"R Wesolowski","year":"2010","unstructured":"Wesolowski R, Budd GT . Use of chemotherapy for patients with bone and soft-tissue sarcomas. Cleve Clin J Med 2010; 77 (Suppl 1): S23\u2013S26.","journal-title":"Cleve Clin J Med"},{"key":"BFtpj201133_CR4","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.ejca.2005.08.026","volume":"41","author":"G Bacci","year":"2005","unstructured":"Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P . Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 2005; 41: 2836\u20132845.","journal-title":"Eur J Cancer"},{"key":"BFtpj201133_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.9-4-422","volume":"9","author":"N Marina","year":"2004","unstructured":"Marina N, Gebhardt M, Teot L, Gorlick R . Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422\u2013441.","journal-title":"Oncologist"},{"key":"BFtpj201133_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/cncr.21724","volume":"106","author":"G Bacci","year":"2006","unstructured":"Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P . Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154\u20131161.","journal-title":"Cancer"},{"key":"BFtpj201133_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00432-007-0330-x","volume":"134","author":"JC Clark","year":"2008","unstructured":"Clark JC, Dass CR, Choong PF . A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 281\u2013297.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFtpj201133_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2003.03.144","volume":"21","author":"M Serra","year":"2003","unstructured":"Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003; 21: 536\u2013542.","journal-title":"J Clin Oncol"},{"key":"BFtpj201133_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/pbc.22178","volume":"53","author":"J Bajpai","year":"2009","unstructured":"Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009; 53: 1035\u20131039.","journal-title":"Pediatr Blood Cancer"},{"key":"BFtpj201133_CR10","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.22009","volume":"119","author":"MV Le","year":"2006","unstructured":"Le MV, Longy M, Bonaiti-Pellie C, Bui B, Houede N, Coindre JM et al. Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients. Int J Cancer 2006; 119: 1732\u20131735.","journal-title":"Int J Cancer"},{"key":"BFtpj201133_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1517\/17530050802608496","volume":"3","author":"C Kong","year":"2009","unstructured":"Kong C, Hansen MF . Biomarkers in osteosarcoma. Expert Opin Med Diagn 2009; 3: 13\u201323.","journal-title":"Expert Opin Med Diagn"},{"key":"BFtpj201133_CR12","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-10-0284","volume":"16","author":"J Smida","year":"2010","unstructured":"Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 2010; 16: 4256\u20134267.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201133_CR13","first-page":"1513","volume":"11","author":"EL Goode","year":"2002","unstructured":"Goode EL, Ulrich CM, Potter JD . Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513\u20131530.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201133_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ . Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291\u20131295.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201133_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","volume":"24","author":"E Reed","year":"1998","unstructured":"Reed E . Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331\u2013344.","journal-title":"Cancer Treat Rev"},{"key":"BFtpj201133_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","volume":"91","author":"J Stoehlmacher","year":"2004","unstructured":"Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344\u2013354.","journal-title":"Br J Cancer"},{"key":"BFtpj201133_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kwi018","volume":"161","author":"S Benhamou","year":"2005","unstructured":"Benhamou S, Sarasin A . ERCC2\/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005; 161: 1\u201314.","journal-title":"Am J Epidemiol"},{"key":"BFtpj201133_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/carcin\/21.5.965","volume":"21","author":"EJ Duell","year":"2000","unstructured":"Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000; 21: 965\u2013971.","journal-title":"Carcinogenesis"},{"key":"BFtpj201133_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","volume":"21","author":"RM Lunn","year":"2000","unstructured":"Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21: 551\u2013555.","journal-title":"Carcinogenesis"},{"key":"BFtpj201133_CR20","first-page":"1354","volume":"61","author":"MR Spitz","year":"2001","unstructured":"Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354\u20131357.","journal-title":"Cancer Res"},{"key":"BFtpj201133_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/tpj.2009.19","volume":"9","author":"D Caronia","year":"2009","unstructured":"Caronia D, Patino-Garcia A, Milne RL, Zalacain-Diez M, Pita G, Alonso MR et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009; 9: 347\u2013353.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201133_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/annonc\/mdj135","volume":"17","author":"R De las Penas","year":"2006","unstructured":"De las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R et al. Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17: 668\u2013675.","journal-title":"Ann Oncol"},{"key":"BFtpj201133_CR23","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","volume":"22","author":"S Gurubhagavatula","year":"2004","unstructured":"Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594\u20132601.","journal-title":"J Clin Oncol"},{"key":"BFtpj201133_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2009.01.002","volume":"113","author":"HS Kim","year":"2009","unstructured":"Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009; 113: 264\u2013269.","journal-title":"Gynecol Oncol"},{"key":"BFtpj201133_CR25","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1200\/JCO.2008.16.1323","volume":"26","author":"TC Krivak","year":"2008","unstructured":"Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 2008; 26: 3598\u20133606.","journal-title":"J Clin Oncol"},{"key":"BFtpj201133_CR26","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2006.05.8768","volume":"24","author":"M Quintela-Fandino","year":"2006","unstructured":"Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006; 24: 4333\u20134339.","journal-title":"J Clin Oncol"},{"key":"BFtpj201133_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/107327480301000404","volume":"10","author":"R Rosell","year":"2003","unstructured":"Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B . Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10: 297\u2013305.","journal-title":"Cancer Control"},{"key":"BFtpj201133_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.bjc.6603290","volume":"95","author":"S Sakano","year":"2006","unstructured":"Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006; 95: 561\u2013570.","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"BFtpj201133_CR29","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.ygyno.2007.07.043","volume":"107","author":"JS Saldivar","year":"2007","unstructured":"Saldivar JS, Wu X, Follen M, Gershenson D . Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 2007; 107 (Suppl 1): S56\u2013S71.","journal-title":"Gynecol Oncol"},{"key":"BFtpj201133_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/FPC.0b013e32832f3010","volume":"19","author":"PA Bradbury","year":"2009","unstructured":"Bradbury PA, Kulke MH, Rebecca SH, Zhou W, Ma C, Xu W et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009; 19: 613\u2013625.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201133_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/carcin\/23.4.599","volume":"23","author":"SM Hou","year":"2002","unstructured":"Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002; 23: 599\u2013603.","journal-title":"Carcinogenesis"},{"key":"BFtpj201133_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7150\/ijms.4.59","volume":"4","author":"C Kiyohara","year":"2007","unstructured":"Kiyohara C, Yoshimasu K . Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007; 4: 59\u201371.","journal-title":"Int J Med Sci"},{"key":"BFtpj201133_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/carcin\/bgi280","volume":"27","author":"G Matullo","year":"2006","unstructured":"Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006; 27: 997\u20131007.","journal-title":"Carcinogenesis"},{"key":"BFtpj201133_CR34","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1158\/1055-9965.2053.13.12","volume":"13","author":"MB Terry","year":"2004","unstructured":"Terry MB, Gammon MD, Zhang FF, Eng SM, Sagiv SK, Paykin AB et al. Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 2053\u20132058.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201133_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/carcin\/22.6.899","volume":"22","author":"U Vogel","year":"2001","unstructured":"Vogel U, Hedayati M, Dybdahl M, Grossman L, Nexo BA . Polymorphisms of the DNA repair gene XPD: correlations with risk of basal cell carcinoma revisited. Carcinogenesis 2001; 22: 899\u2013904.","journal-title":"Carcinogenesis"},{"key":"BFtpj201133_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.mrfmmm.2003.11.001","volume":"546","author":"U Vogel","year":"2004","unstructured":"Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A et al. Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res 2004; 546: 65\u201374.","journal-title":"Mutat Res"},{"key":"BFtpj201133_CR37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11255-009-9560-y","volume":"41","author":"H Wen","year":"2009","unstructured":"Wen H, Ding Q, Fang ZJ, Xia GW, Fang J . Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol 2009; 41: 855\u2013864.","journal-title":"Int Urol Nephrol"},{"key":"BFtpj201133_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cancergencyto.2004.01.027","volume":"154","author":"HP Yu","year":"2004","unstructured":"Yu HP, Wang XL, Sun X, Su YH, Wang YJ, Lu B et al. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2004; 154: 10\u201315.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFtpj201133_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1158\/1055-9965.EPI-04-0612","volume":"14","author":"W Zhou","year":"2005","unstructured":"Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 491\u2013496.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201133_CR40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ijc.23410","volume":"123","author":"J Doecke","year":"2008","unstructured":"Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer 2008; 123: 174\u2013180.","journal-title":"Int J Cancer"},{"key":"BFtpj201133_CR41","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/carcin\/bgi232","volume":"27","author":"S Zienolddiny","year":"2006","unstructured":"Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006; 27: 560\u2013567.","journal-title":"Carcinogenesis"},{"key":"BFtpj201133_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFtpj201133_CR43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables. J Roy Stat Soc B 1972; 34: 187\u2013220.","journal-title":"J Roy Stat Soc B"},{"key":"BFtpj201133_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/9780470773666","volume-title":"Statistical Methods in Medical Res","author":"P Armitage","year":"2002","unstructured":"Armitage P, Berry G, Matthews JNS . Statistical Methods in Medical Res, 4th edn. Blackwell Science: Oxford, 2002."},{"key":"BFtpj201133_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","volume":"152","author":"G Ottaviani","year":"2009","unstructured":"Ottaviani G, Jaffe N . The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3\u201313.","journal-title":"Cancer Treat Res"},{"key":"BFtpj201133_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1349-7006.2007.00692.x","volume":"99","author":"R Nakayama","year":"2008","unstructured":"Nakayama R, Sato Y, Masutani M, Ogino H, Nakatani F, Chuman H et al. Association of a missense single nucleotide polymorphism, Cys1367Arg of the WRN gene, with the risk of bone and soft tissue sarcomas in Japan. Cancer Sci 2008; 99: 333\u2013339.","journal-title":"Cancer Sci"},{"key":"BFtpj201133_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000164220","volume":"75","author":"X He","year":"2008","unstructured":"He X, Ye F, Zhang J, Cheng Q, Shen J, Chen H . Susceptibility of XRCC3, XPD, and XPG genetic variants to cervical carcinoma. Pathobiology 2008; 75: 356\u2013363.","journal-title":"Pathobiology"},{"key":"BFtpj201133_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-010-0751-0","volume":"123","author":"Z Jiang","year":"2010","unstructured":"Jiang Z, Li C, Xu Y, Cai S, Wang X . Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat 2010; 123: 203\u2013212.","journal-title":"Breast Cancer Res Treat"},{"key":"BFtpj201133_CR49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1055-9965.EPI-07-2507","volume":"17","author":"F Wang","year":"2008","unstructured":"Wang F, Chang D, Hu FL, Sui H, Han B, Li DD et al. DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev 2008; 17: 507\u2013517.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201133_CR50","doi-asserted-by":"crossref","unstructured":"Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH . The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Med Oncol; published online 30 November 2010; doi:10.1007\/s12032-010-9501-8 [e-pub ahead of print].","DOI":"10.1007\/s12032-010-9501-8"},{"key":"BFtpj201133_CR51","first-page":"1163","volume":"28","author":"CZ Zhang","year":"2009","unstructured":"Zhang CZ, Chen ZP, Xu CQ, Ning T, Li DP, Hou RP . Correlation of XPD gene with susceptibility to gastric cancer. Ai Zheng 2009; 28: 1163\u20131167.","journal-title":"Ai Zheng"},{"key":"BFtpj201133_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1055-9965.EPI-03-0053","volume":"13","author":"BA Rybicki","year":"2004","unstructured":"Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS . DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 23\u201329.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201133_CR53","first-page":"629","volume":"24","author":"ZK Stadler","year":"2010","unstructured":"Stadler ZK, Gallagher DJ, Thom P, Offit K . Genome-wide association studies of cancer: principles and potential utility. Oncology 2010; 24: 629\u2013637.","journal-title":"Oncology"},{"key":"BFtpj201133_CR54","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1200\/JCO.2009.25.7816","volume":"28","author":"ZK Stadler","year":"2010","unstructured":"Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, Hurley KE et al. Genome-wide association studies of cancer. J Clin Oncol 2010; 28: 4255\u20134267.","journal-title":"J Clin Oncol"},{"key":"BFtpj201133_CR55","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.ajhg.2010.05.002","volume":"86","author":"MC Wu","year":"2010","unstructured":"Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ et al. Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet 2010; 86: 929\u2013942.","journal-title":"Am J Hum Genet"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T11:57:34Z","timestamp":1741435054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,9]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["BFtpj201133"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2011.33","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,9]]},"assertion":[{"value":"21 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}